Apeiron Biotechnology (Oral CDK7 Inhibitor Program) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Apeiron Biotechnology (Oral CDK7 Inhibitor Program) General Information

Description

Operator of oral cyclin-dependent kinase inhibitor program catering to cancer research.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Shanghai
  • China
Primary Industry
Buildings and Property
Other Industries
Discovery Tools (Healthcare)
Acquirer
Exscientia
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Shanghai
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apeiron Biotechnology (Oral CDK7 Inhibitor Program) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Apeiron Biotechnology (Oral CDK7 Inhibitor Program)‘s full profile, request access.

Request a free trial

Apeiron Biotechnology (Oral CDK7 Inhibitor Program) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Apeiron Biotechnology (Oral CDK7 Inhibitor Program)‘s full profile, request access.

Request a free trial

Apeiron Biotechnology (Oral CDK7 Inhibitor Program) FAQs

  • Where is Apeiron Biotechnology (Oral CDK7 Inhibitor Program) headquartered?

    Apeiron Biotechnology (Oral CDK7 Inhibitor Program) is headquartered in Shanghai, China.

  • What industry is Apeiron Biotechnology (Oral CDK7 Inhibitor Program) in?

    Apeiron Biotechnology (Oral CDK7 Inhibitor Program)’s primary industry is Buildings and Property.

  • Is Apeiron Biotechnology (Oral CDK7 Inhibitor Program) a private or public company?

    Apeiron Biotechnology (Oral CDK7 Inhibitor Program) is a Private company.

  • What is the current valuation of Apeiron Biotechnology (Oral CDK7 Inhibitor Program)?

    The current valuation of Apeiron Biotechnology (Oral CDK7 Inhibitor Program) is .

  • What is Apeiron Biotechnology (Oral CDK7 Inhibitor Program)’s current revenue?

    The current revenue for Apeiron Biotechnology (Oral CDK7 Inhibitor Program) is .

  • Who are Apeiron Biotechnology (Oral CDK7 Inhibitor Program)’s investors?

    Apeiron (Drug Discovery) has invested in Apeiron Biotechnology (Oral CDK7 Inhibitor Program).

  • When was Apeiron Biotechnology (Oral CDK7 Inhibitor Program) acquired?

    Apeiron Biotechnology (Oral CDK7 Inhibitor Program) was acquired on 19-Jul-2024.

  • Who acquired Apeiron Biotechnology (Oral CDK7 Inhibitor Program)?

    Apeiron Biotechnology (Oral CDK7 Inhibitor Program) was acquired by Exscientia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process